Meet the ELOCTATE Peers, hear their stories, and learn why they count on the bleed protection offered by ELOCTATE prophylaxis.
*Data on file. Waltham, MA; Bioverativ Therapeutics Inc., an affiliate of Sanofi.
Note: These are personal accounts of ELOCTATE Peers. Please talk to your healthcare provider about whether ELOCTATE may be right for you. Individual results may vary.
The recommended starting regimen is 50 IU/kg every 4 days as directed by your doctor. In children under 6 years of age, the recommended starting regimen is 50 IU/kg administered twice weekly. The regimen can be adjusted based on your body's individual response.
ADVATE® [Antihemophilic Factor (Recombinant)] is a registered trademark of Baxalta Incorporated, a Takeda company.
Community Relations and Education Managers (or CoRe, for short) live and work all across the United States. CoRe team members are advocates and people with decades of experience in Hemophilia. They're available to answer your questions, educate, or just to talk. Use our handy CoRe Locator to find the CoRe team member nearest you.
You know you're leaving the ELOCTATE website?
If you're okay with that, we're okay with that.
Come back soon!
You’re being directed to the ELOCTATE Healthcare Professional website. If you’re okay with that, we’re okay with that.
Come back soon!
INDICATION ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with Hemophilia A (congenital Factor VIII deficiency). Your healthcare provider may give you ELOCTATE when you have surgery.
Important Safety Information and Indication
IMPORTANT SAFETY INFORMATION
Do not use ELOCTATE if you have had an allergic reaction to it in the past.
Tell your healthcare provider if you have or have had any medical problems, take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines, have any allergies, are breastfeeding, are pregnant or planning to become pregnant, or have been told you have inhibitors (antibodies) to Factor VIII.
Allergic reactions may occur with ELOCTATE. Call your healthcare provider or get emergency treatment right away if you have any of the following symptoms: difficulty breathing, chest tightness, swelling of the face, rash, or hives.
Your body can also make antibodies called "inhibitors" against ELOCTATE, which may stop ELOCTATE from working properly.
Additional common side effects of ELOCTATE are headache, rash, joint pain, muscle pain and general discomfort.
If you have risk factors for developing abnormal blood clots in your body, such as an indwelling venous catheter, treatment with Factor VIII may increase this risk.
These are not all the possible side effects of ELOCTATE. Talk to your healthcare provider right away about any side effect that bothers you or that does not go away, or if bleeding is not controlled after using ELOCTATE.
ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with Hemophilia A (congenital Factor VIII deficiency). Your healthcare provider may give you ELOCTATE when you have surgery.